Venus MedTech Reports Positive Interim Results for Cardiovalve Tricuspid Valve Replacement System
I'm PortAI, I can summarize articles.
Venus MedTech announced positive interim clinical results from its Target Study on the Cardiovalve transcatheter tricuspid valve replacement system. The study involved 125 patients across 25 sites in Germany, Spain, Italy, Canada, and the UK. The interim data showed an average device operation time of 58±29 minutes. The system demonstrated strong efficacy in treating severe tricuspid regurgitation and received positive recognition from global clinical experts. Venus MedTech remains committed to advancing its global clinical development and regulatory registration of Cardiovalve.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments